Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR22293-58] to VEGF Receptor 3
- Suitable for: Flow Cyt
- Reacts with: Human
Product nameAnti-VEGF Receptor 3 antibody [EPR22293-58]
See all VEGF Receptor 3 primary antibodies
DescriptionRabbit monoclonal [EPR22293-58] to VEGF Receptor 3
Tested applicationsSuitable for: Flow Cytmore details
Unsuitable for: ICC/IF,IHC-P or WB
Species reactivityReacts with: Human
Recombinant fragment within Human VEGF Receptor 3 aa 1-750. The exact sequence is proprietary.
Database link: P35916
- Flow cyt: HEL cells.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol, 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab243233 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
FunctionReceptor for VEGFC. Has a tyrosine-protein kinase activity.
Tissue specificityPlacenta, lung, heart, and kidney, does not seem to be expressed in pancreas and brain.
Involvement in diseaseDefects in FLT4 are the cause of lymphedema hereditary type 1A (LMPH1A) [MIM:153100]; also known as Nonne-Milroy lymphedema or Milroy disease. Hereditary lymphedema is a chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment.
Note=Defects in FLT4 are found in juvenile hemangioma. Juvenile hemangiomas are the most common tumors of infancy, occurring as many as 10% of all births. These benign vascular lesions enlarge rapidly during the first year of life by hyperplasia of endothelial cells and attendant pericytes, and then spontaneously involute over a period of years, leaving loose fibrofatty tissue.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain.
- Information by UniProt
- EC 22.214.171.124 antibody
- flt 4 antibody
- FLT-4 antibody
Flow cytometric analysis of MCF7 (human breast adenocarcinoma cell line) (Left panel) and HEL (human bone marrow erythroleukemia cell line) (Right panel) cell lines labeling VEGF Receptor 3 with ab243233 at 1/500 (red) compared with Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077), at 1/2000 dilution was used as the secondary antibody.
Gated on viable cells.
Negative control: MCF7 (PMID: 18538738).
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab243233 has not yet been referenced specifically in any publications.